Trials
3 active
6 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants in both Phase 2B and Phase 3 will be randomized to received study drug tazbentetol or placebo tablets. Participants in the open-label extension phase will receive the dose determined from Phase 2.”In the company’s words, NCT07325591 on ClinicalTrials.gov
- Main trialPhase 2/3
- “The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.”In the company’s words, NCT07325591 on ClinicalTrials.gov
- Other names
- Tazbentetol
Other drugs for Amyotrophic Lateral Sclerosis
Coming up1
- 31 Dec 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 31 Dec 2027 | Efficacy and Safety of Tazbentetol in ALS Participants | |
| Phase 2Active, not recruiting | Dec 2025 | Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD) | |
| Phase 2Active, not recruiting | Mar 2026 | Study of SPG302 in Adults With Schizophrenia | |
| Phase 2Terminated | 30 Jun 2025 | Extension Study of Participants From SPG302-ALS-001 | |
| Phase 2Terminated | 30 Jul 2025 | Extension Study of Participants From SPG302-ALZ-101 | |
| Phase 1Completed | 27 Jun 2025 | Study of SPG302 in Healthy Volunteers and ALS Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026